Early tumor-infiltrating dendritic cells change their characteristics drastically in association with murine melanoma progression

Journal of Investigative Dermatology

Volumn 136, Issue 1, 2016, Pages 146-153

  Nakahara, Takeshi ^a   Oba, Junna ^a   Shimomura, Chie ^a   Kido Nakahara, Makiko ^a   Furue, Masutaka ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD45 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; GLYCOPROTEIN P 15095; GRANZYME B; INTERLEUKIN 10; INTERLEUKIN 6; PERFORIN; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD8+ T LYMPHOCYTE; CELL FUNCTION; CELL INFILTRATION; CELL MATURATION; CELL PROLIFERATION; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; FLOW CYTOMETRY; IMMUNOCOMPETENT CELL; IMMUNOSTIMULATION; IN VIVO STUDY; LYMPH NODE; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; MELANOMA CELL; MIXED LYMPHOCYTE REACTION; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE ACTIVATION; TUMOR GROWTH; TUMOR INFILTRATING DENDRITIC CELL; TUMOR MICROENVIRONMENT; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CELL TRANSFORMATION; CYTOLOGY; DISEASE COURSE; DISEASE MODEL; ENZYME LINKED IMMUNOSORBENT ASSAY; PATHOLOGY; PATHOPHYSIOLOGY; PROCEDURES; RANDOMIZATION; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SKIN TUMOR; TUMOR VOLUME;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; MELANOMA; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; RANDOM ALLOCATION; REAL-TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SKIN NEOPLASMS; TUMOR BURDEN;

EID: 84959484128     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/JID.2015.359     Document Type: Article

References (32)

1. Ataera H, Hyde E, Price KM, Stoitzner P, Ronchese F. Murine melanomainfiltrating dendritic cells are defective in antigen presenting function regardless of the presence of CD4CD25 regulatory T cells. PLoS One 2011;6:e17515.
2. Diao J, Zhao J, Winter E, Cattral MS. Tumors suppress in situ proliferation of cytotoxic T cells by promoting differentiation of Gr-1 (+) conventional dendritic cells through IL-6. J Immunol 2011;186:5058-67.
3. Dikov MM, Ohm JE, Ray N, et al.. Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation. J Immunol 2005;174:215-22.
4. Engelhardt JJ, Boldajipour B, Beemiller P, et al.. Marginating dendritic cells of the tumor microenvironment cross-present tumor antigens and stably engage tumor-specific T cells. Cancer Cell 2012;21:402-17.
5. Erdag G, Schaefer JT, Smolkin ME, et al.. Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. Cancer Res 2012;72:1070-80.
6. Fridman WH, Galon J, Pagés F, Tartour E, Sautés-Fridman C, Kroemer G. Prognostic and predictive impact of intra- and peritumoral immune infiltrates. Cancer Res 2011;71:5601-5.
7. Garcia-Plata D, Lessana-Leibowitch M, Palangie A, et al.. Immunophenotype analysis of dendritic cells and lymphocytes associated with cutaneous malignant melanomas. Invasion Metastasis 1995;15:125-34.
8. Gottfried E, Kunz-Schughart LA, Ebner S, et al.. Tumor-derived lactic acid modulates dendritic cell activation and antigen expression. Blood 2006;107:2013-21.
9. Jensen TO, Schmidt H, Møller HJ, et al.. Intratumoral neutrophils and plasmacytoid dendritic cells indicate poor prognosis and are associated with pSTAT3 expression in AJCC stage I/II melanoma. Cancer 2012;118:2476-85.
10. Klarquist JS, Janssen EM. Melanoma-infiltrating dendritic cells: limitations and opportunities of mouse models. Oncoimmunology 2012;1:1584-93.
11. Krempski J, Karyampudi L, Behrens MD, et al.. Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer. J Immunol 2011;186:6905-13.
12. Ladanyi A, Kiss J, Somlai B, et al.. Density of DC-LAMP (+) mature dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor. Cancer Immunol Immunother 2007;56:1459-69.
13. Liu K, Nussenzweig MC. Origin and development of dendritic cells. Immunol Rev 2010;234:45-54.
14. Liu Y, Bi X, Xu S, Xiang J. Tumor-infiltrating dendritic cell subsets of progressive or regressive tumors induce suppressive or protective immune responses. Cancer Res 2005;65:4955-62.
15. Mimura K, Kono K, Takahashi A, Kawaguchi Y, Fujii H. Vascular endothelial growth factor inhibits the function of human mature dendritic cells mediated by VEGF receptor-2. Cancer Immunol Immunother 2007;56:761-70.
16. Moreau A, Hill M, Thébault P, et al.. Tolerogenic dendritic cells actively inhibit T cells through heme oxygenase-1 in rodents and in nonhuman primates. FASEB J 2009;23:3070-7.
17. Movassagh M, Spatz A, Davoust J, et al.. Selective accumulation of mature DC-Lamp+ dendritic cells in tumor sites is associated with efficient T-cellmediated antitumor response and control of metastatic dissemination in melanoma. Cancer Res 2004;64:2192-8.
18. Nakahara T, Uchi H, Lesokhin AM, et al.. Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs. Blood 2010;115:4384-92.
19. Peng W, Ran B, Ma Y, Huang X, Chang Q, Wang X. Dendritic cells transfected with PD-L1 recombinant adenovirus induces T cell suppression and longterm acceptance of allograft transplantation. Cell Immunol 2011;271:73-7.
20. Preynat-Seauve O, Schuler P, Contassot E, Beermann F, Huard B, French LE. Tumor-infiltrating dendritic cells are potent antigen-presenting cells able to activate T cells and mediate tumor rejection. J Immunol 2006;176:61-7.
21. Ramirez-Montagut T, Turk MJ, Wolchok JD, Guevara-Patino JA, Houghton AN. Immunity to melanoma: unraveling the relation of tumor immunity and autoimmunity. Oncogene 2003;22:3180-7.
22. Reis E Sousa C. Dendritic cells in a mature age. Nat Rev Immunol 2006;6:476-83.
23. Sandel MH, Dadabayev AR, Menon AG, et al.. Prognostic value of tumorinfiltrating dendritic cells in colorectal cancer: role of maturation status and intratumoral localization. Clin Cancer Res 2005;11:2576-82.
24. Scarlett UK, Cubillos-Ruiz JR, Nesbeth YC, et al.. In situ stimulation of CD40 and Toll-like receptor 3 transforms ovarian cancer-infiltrating dendritic cells from immunosuppressive to immunostimulatory cells. Cancer Res 2009;69:7329-37.
25. Simonetti O, Goteri G, Lucarini G, et al.. In melanoma changes of immature and mature dendritic cell expression correlate with tumor thickness: an immunohistochemical study. Int J Immunopathol Pharmacol 2007;20:325-33.
26. Sin JI, Park JB, Lee IH, et al.. Intratumoral electroporation of IL-12 cDNA eradicates established melanomas by Trp2 (180-188)-specific CD8p CTLs in a perforin/granzyme-mediated and IFN-g-dependent manner: application of Trp2 (180-188) peptides. Cancer Immunol Immunother 2012;61:1671-82.
27. Steinman RM, Idoyaga J. Features of the dendritic cell lineage. Immunol Rev 2010;234:5-17.
28. Stoitzner P, Green LK, Jung JY, et al.. Inefficient presentation of tumor-derived antigen by tumor-infiltrating dendritic cells. Cancer Immunol Immunother 2008;57:1665-73.
29. Thompson ED, Enriquez HL, Fu YX, Engelhard VH. Tumor masses support naive T cell infiltration, activation, and differentiation into effectors. J Exp Med 2010;207:1791-804.
30. Tran Janco JM, Lamichhane P, Karyampudi L, Knutson KL. Tumor-infiltrating dendritic cells in cancer pathogenesis. J Immunol 2015;194:2985-91.
31. Vermi W, Bonecchi R, Facchetti F, et al.. Recruitment of immature plasmacytoid dendritic cells (plasmacytoid monocytes) and myeloid dendritic cells in primary cutaneous melanomas. J Pathol 2003;200:255-68.
32. Zhao F, Falk C, Osen W, Kato M, Schadendorf D, Umansky V. Activation of p38 mitogen-activated protein kinase drives dendritic cells to become tolerogenic in ret transgenic mice spontaneously developing melanoma. Clin Cancer Res 2009;15:4382-90.